Simon Swift

Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs.

The use of cardiac troponin I (cTnI) to assess the severity of disease and prognosis in 120 dogs presented for cardiac evaluation was analysed. cTnI concentrations were measured using a commercially available assay. Dogs were placed into three groups: group 1, cTnI0.15ng/mL; group 2, cTnI 0.151-1.0ng/mL; group 3, cTnI>1.01ng/mL. Dogs in group 1 were significantly younger (P<0.0001) and had no or stable cardiac diseases and longest survival times, whereas those in groups 2 and 3 had severe cardiac diseases and significantly reduced survival times (P<0.0001). Thirty dogs with initially increased cTnI concentrations had a repeat assay less than 2months later with significant reductions in cTnI concentrations (P=0.005). Initial cTnI concentrations could not differentiate dogs that survived in group 3 from those that did not. However, dogs that survived showed significant cTnI reductions (P=0.015) in the repeated assay in contrast to the dogs that died (P=0.22). It was concluded that cTnI is useful in assessing the prognosis and severity of cardiac diseases in dogs, and progression and response to treatment can be assessed by repeat sampling. cTnI concentrations >1.0ng/mL and persistent increases in cTnI concentrations are indicators of a poor prognosis in dogs with cardiac disease.

The Cardiac Biomarker NT-proBNP Is Increased in Dogs with Azotemia

BACKGROUND Amino-terminal probrain natriuretic peptide (NT-proBNP) has been proposed as a useful biomarker for heart disease in dogs. In humans, decreased glomerular filtration rate (GFR) increases NT-proBNP. OBJECTIVE To investigate whether decreased GFR as indicated by plasma creatinine concentration is associated with increased NT-proBNP in dogs without heart disease. ANIMALS Four groups of dogs: healthy (n= 39), azotemic (n= 36), heart disease (n= 37), and congestive heart failure (CHF) (n= 7) presented to 2 teaching hospitals. METHODS Prospective observational cohort study. Plasma creatinine concentration and NT-proBNP were measured in every dog. Nonparametric tests were used to compare the differences among groups. The median and actual results for each group were compared with the manufacturers recommended and previously published suggestions for cut-off values for diagnosis of heart disease. RESULTS Median (range) plasma creatinine concentration was 1.47 (1.06-1.70), 4.36 (1.74-15.6), 1.22 (0.69-1.91), and 1.45 (0.63-1.64) mg/dL and median (range) NT-proBNP was 118 (2-673), 556 (37-1,819), 929 (212-5,658), and 3,144 (432-5,500) pmol/L for the healthy, azotemic, heart disease, and CHF groups, respectively. Pair-wise comparison indicated a significant difference among all groups for NT-proBNP (P< or = .049). Plasma creatinine concentration was significantly higher in the azotemic group compared with other groups (P < .001) but there was no significant among other groups. Application of 3 recommended cut-off values led to misclassification of dogs with azotemia as having heart disease. CONCLUSIONS Azotemia results in NT-proBNP being increased to concentrations reported as diagnostic of heart disease or heart failure in dogs. Care should be employed when interpreting the results of NT-proBNP in patients with known or possible increased plasma creatinine concentration.

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Myxomatous Mitral Valve Disease Receiving Pimobendan or Benazepril: The QUEST Study

BACKGROUND Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogs. OBJECTIVES To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD. ANIMALS A total of 260 dogs in CHF because of MMVD. METHODS A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day). Differences in outcome variables and time to intensification of CHF treatment were compared. RESULTS A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = .0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030). Incidence of arrhythmias was similar in treatment groups. CONCLUSIONS AND CLINICAL IMPORTANCE Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment. Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.

Balloon Valvuloplasty for Treatment of Pulmonic Stenosis in English Bulldogs with an Aberrant Coronary Artery

BACKGROUND English Bulldogs (EB) with pulmonic stenosis (PS) sometimes have an aberrant coronary artery (CA) type R2A encircling the pulmonary artery (PA). Balloon valvuloplasty (BV) is treatment of choice for severe PS, but is considered to be contraindicated in dogs with aberrant CA. HYPOTHESIS Conservative BV in EB with aberrant CA is safe and improves clinical signs and quality of life. ANIMALS Four client-owned EB with severe PS were retrospectively reviewed/analysed. METHODS Retrospective study: Case records, echocardiography, BV, and follow-up investigations of EB diagnosed with severe PS and treated with BV were reviewed. The ratios of PA to aortic (Ao) velocity time integral (VTI) were calculated to assess progression/improvement of PS. RESULTS An aberrant CA was confirmed on angiography in all EB. Conservative BV was performed, using a balloon of the size of the PA annulus or smaller (0.6-1 x PA annulus size). All dogs survived the procedure, but only a mild reduction in pressure gradient was achieved. There was an improvement in PA to Ao VTI in 3 of 4 dogs (P < or = .017), which were free of evidence of congestive heart failure (CHF) 5, 10, and 15 months after BV. One dog that had right-sided CHF when BV was performed died due to progressive right-sided CHF within 3 months. CONCLUSIONS Conservative BV in EB might be safe and might improve quality and quantity of life.

Aetiology and outcome in 90 cats presenting with dyspnoea in a referral population

Objectives: Dyspnoea is an unspecific severe presenting sign, which can be life threatening and requires prompt treatment. Dyspnoeic cats often have significant underlying disease. Underlying aetiologies in cats that presented with dyspnoea were reviewed, and associations with patient signalment and outcome were investigated. Methods: The case records of 90 dyspnoeic cats were retrospectively reviewed and separated into different groups depending on aetiology (cardiac, respiratory, neoplastic and trauma). Duration of clinical signs, presentation, hospitalisation length and survival were analysed. Results: Cardiac (38 per cent), respiratory (32 per cent) and neoplastic (20 per cent) diseases were common causes of feline dyspnoea. Cats with respiratory causes had longer duration of clinical signs (P<0·001) before presentation. Cats with neoplasia were significantly older (P<0·001). No significant difference in respiratory rates was present between the groups (P = 0·154). High heart rates (P<0·001) and abnormalities on cardiac auscultation were more likely in the cardiac group. Clinical Significance: Frequent causes of dyspnoea in cats were cardiac disease followed by respiratory causes and neoplastic conditions. Heart rate on presentation and presence of heart murmurs or gallops are useful to identify cardiac causes. Improved proportion surviving was found in the respiratory group (P = 0·027), whereas cats with neoplasia had the worst outcome.

English springer spaniels with significant bradyarrhythmias--presentation, troponin I and follow-up after pacemaker implantation.

OBJECTIVES English springer spaniels (ESS) are one of the most frequently presented breeds for pacemaker implantation in the UK and may do so at an early age. In comparison to dogs of other breeds (non-ESS) presenting for pacemaker implantation, cardiac troponin I (cTnI), the outcome and survival of ESS were investigated. METHODS Case records of dogs receiving pacemaker implantation were retrospectively reviewed. RESULTS Between September 2004 and October 2008, 58 dogs were presented to the Small Animal Teaching Hospital, University of Liverpool for pacemaker implantation. ESS (n=10) was the second most commonly presented breed. ESS were significantly younger than non-ESS (P=0.022). cTnI values were elevated on presentation and a significant reduction was present after pacemaker implantation (P=0.008) in all dogs. No significant difference in initial cTnI was identified comparing ESS and non-ESS (P=0.45) and median survival times were similar (P=0.37). CLINICAL SIGNIFICANCE ESS may be predisposed to bradyarrhythmias requiring pacemaker implantation. They present at a significantly younger age than non-ESS. Survival times between ESS and non-ESS were similar, despite ESS being paced at a younger age. However, pacemaker implantation is recommended in ESS, as median survival times of 30 months with a good quality of life were achieved.

Implantable loop recorders: a viable diagnostic tool in veterinary medicine.

OBJECTIVE The purpose of this study was to investigate whether implantable loop recorders could be used in the diagnosis of unexplained collapse in dogs. METHODS The medical records of six dogs presented to the University of Liverpool Small Animal Teaching Hospital between May 2003 and October 2006 for further evaluation of intermittent syncopal episodes, collapse or episodic weakness, were reviewed. All these dogs underwent standard investigations and had implantable loop recorders placed. RESULTS A provisional diagnosis of supraventricular tachycardia was made in one dog, and diagnoses of exclusion of arrhythmogenic right ventricular cardiomyopathy and idiopathic epilepsy was made in two dogs. One dog suffered no further syncopal episodes, a diagnosis was not reached in another dog and the final dog was lost to follow-up. CLINICAL SIGNIFICANCE The implantable loop recorder can be used successfully for the diagnosis of unexplained collapse in dogs.

Specialisation, self-assessment and measuring competency.

THERE is a recurring theme of correspondence in the veterinary press regarding referrals and the role of ‘specialists’ in veterinary medicine. Comment often centres on the relevance of qualification and accreditation of specialists in the veterinary field and the merits or otherwise of those carrying higher (Diplomate or RCVS Recognised Specialist) qualifications when compared with those without such qualifications. The debate falls back to the claimed omnicompetence of veterinary surgeons, with an individual veterinary surgeons competence in any given procedure (diagnostic or therapeutic) being left, ultimately, to self-judgement. This self-assessment of competence is enshrined in the RCVS Guide to Professional Conduct. Section 2D, Maintaining Practice Standards, paragraph 34 reads: ‘All veterinary surgeons should recognise when a case is outside their area of competence and be prepared to refer it to a …

Treatment of congestive heart failure in dogs

SIR, — Five years ago we wrote to The Veterinary Record asking colleagues to help us recruit cases to a study — the QUEST study — evaluating the effect of pimobendan compared with benazepril in dogs with congestive heart failure secondary to myxomatous mitral valve disease (mmvd) ([Boswood and